Please contact our clinical trial director, Allison Calvanese at (727) 498-6176.

OPT-302-1005 Coast Study (NCT04757636)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1004 Shore Study (NCT04757610)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2103 Bioreactor Study (NCT04832724)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2104 Atmosphere Study (NCT04704921)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1005 Coast Study (NCT04757636)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1004 Shore Study (NCT04757610)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2103 Bioreactor Study (NCT04832724)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2104 Atmosphere Study (NCT04704921)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1005 Coast Study (NCT04757636)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1004 Shore Study (NCT04757610)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2103 Bioreactor Study (NCT04832724)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2104 Atmosphere Study (NCT04704921)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1005 Coast Study (NCT04757636)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1004 Shore Study (NCT04757610)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2103 Bioreactor Study (NCT04832724)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2104 Atmosphere Study (NCT04704921)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1005 Coast Study (NCT04757636)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

OPT-302-1004 Shore Study (NCT04757610)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2103 Bioreactor Study (NCT04832724)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)

RGX-314-2104 Atmosphere Study (NCT04704921)

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and
Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with
Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration
(nAMD)